DataMeds AI, Inc. Common Stock (MEDS) is a publicly traded the market company. As of November 2, 2026, MEDS trades at $1.93 with a market cap of $8.67M and a P/E ratio of -1.74. MEDS moved +0.52% today. Year to date, MEDS is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.82 to $12.31. Rallies surfaces MEDS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DataMeds AI restores Nasdaq equity compliance and proposes healthcare IP deals: DataMeds AI regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement on October 19, 2026, but remains subject to delisting if its next periodic report fails to demonstrate compliance. It also signed an amended, nonbinding agreement for healthcare IP transactions targeted to close in the fourth quarter of 2026, subject to conditions.
| Metric | Value |
|---|---|
| Price | $1.93 |
| Market Cap | $8.67M |
| P/E Ratio | -1.74 |
| EPS | $-2.10 |
| Dividend Yield | 1.50% |
| 52-Week High | $12.31 |
| 52-Week Low | $0.82 |
| Volume | 192.23K |
| Avg Volume | 0 |
| Revenue (TTM) | $810.98K |
| Net Income | $-37.95M |
| Gross Margin | 0.00% |
MEDS analyst coverage data. Average price target: $0.00.